Mostrar el registro sencillo del ítem
From Chronodisruption to Sarcopenia: The Therapeutic Potential of Melatonin
dc.contributor.author | Fernández Martínez, José | |
dc.contributor.author | Ramírez Casas, Yolanda | |
dc.contributor.author | Yang, Yang | |
dc.contributor.author | Aranda Martínez, Paula | |
dc.contributor.author | Martínez Ruiz, Laura | |
dc.contributor.author | Escames Rosa, Germaine | |
dc.contributor.author | Acuña Castroviejo, Darío | |
dc.date.accessioned | 2024-04-17T10:58:56Z | |
dc.date.available | 2024-04-17T10:58:56Z | |
dc.date.issued | 2023-12-12 | |
dc.identifier.citation | Fernández-Martínez, J.; Ramírez-Casas, Y.; Yang, Y.; Aranda-Martínez, P.;Martínez-Ruiz, L.; Escames, G.; Acuña-Castroviejo, D. From Chronodisruption to Sarcopenia: The Therapeutic Potential ofMelatonin. Biomolecules 2023, 13, 1779. https://doi.org/10.3390/biom13121779 | es_ES |
dc.identifier.uri | https://hdl.handle.net/10481/90834 | |
dc.description.abstract | Sarcopenia is an age-related condition that involves a progressive decline inmusclemass and function, leading to increased risk of falls, frailty, andmortality. Although the exactmechanisms are not fully understood, aging-related processes like inflammation, oxidative stress, reduced mitochondrial capacity, and cell apoptosis contribute to this decline. Disruption of the circadian system with age may initiate these pathways in skeletal muscle, preceding the onset of sarcopenia. At present, there is no pharmacological treatment for sarcopenia, only resistance exercise and proper nutrition may delay its onset. Melatonin, derived from tryptophan, emerges as an exceptional candidate for treating sarcopenia due to its chronobiotic, antioxidant, and anti-inflammatory properties. Its impact on mitochondria and organelle, where it is synthesized and crucial in aging skeletal muscle, further highlights its potential. In this review, we discuss the influence of clock genes in muscular aging, with special reference to peripheral clock genes in the skeletal muscle, as well as their relationship with melatonin, which is proposed as a potential therapy against sarcopenia. | es_ES |
dc.description.sponsorship | Instituto de Salud Carlos III, grant numbers PI19-01372 and CB/10/00238 | es_ES |
dc.description.sponsorship | FPU fellowship from the Ministerio de Universidades, Spain | es_ES |
dc.description.sponsorship | PFIS fellowship from the Instituto de Salud Carlos III | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | MDPI | es_ES |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Aging | es_ES |
dc.subject | Chronodisruption | es_ES |
dc.subject | Clock genes | es_ES |
dc.title | From Chronodisruption to Sarcopenia: The Therapeutic Potential of Melatonin | es_ES |
dc.type | journal article | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.identifier.doi | 10.3390/biom13121779 | |
dc.type.hasVersion | VoR | es_ES |